Modality
Degrader
MOA
PLK4i
Target
PARP
Pathway
Sphingolipid
Huntington's
Development Pipeline
Preclinical
Dec 2019
→ Mar 2026
PreclinicalCurrent
NCT04210694
1,946 pts·Huntington's
2019-12→2026-03·Active
1,946 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-03-044w agoInterim· Huntington's
Trial Timeline
2020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2
Preclinical
Active
Catalysts
Interim
2026-03-04 · 4w ago
Huntington's
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04210694 | Preclinical | Huntington's | Active | 1946 | DOR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Miriosocimab | Pfizer | Phase 1 | PARP | |
| NVO-2974 | Novo Nordisk | NDA/BLA | PARP | |
| AMG-2597 | Amgen | Phase 2/3 | CD38 | |
| Semainavolisib | Gilead Sciences | Phase 2 | PARP | |
| REG-861 | Regeneron | Phase 2 | PARP | |
| Riluinavolisib | Moderna | NDA/BLA | KIF18A | |
| CRS-337 | CRISPR Therapeutics | Phase 2/3 | PARP | |
| Lisonesiran | Arvinas | Phase 1/2 | PARP | |
| Liravorutinib | Biomea Fusion | Phase 1/2 | GPRC5D | |
| CSL-7919 | CSL Limited | Preclinical | BTK |